Neutralizing Activity of Saliva against Cytomegalovirus

  title={Neutralizing Activity of Saliva against Cytomegalovirus},
  author={Frances M. Saccoccio and Mary Gallagher and Stuart P. Adler and Michael A Mcvoy},
  journal={Clinical and Vaccine Immunology},
  pages={1536 - 1542}
ABSTRACT Congenital cytomegalovirus (CMV) disease is the leading cause of permanent disability in neonates in the United States. Neutralizing antibodies in saliva may protect against maternal CMV infection by blocking viral entry into oral epithelial cells, but the antibody response to CMV in the saliva following natural infection is not well characterized. Saliva specimens from naturally infected individuals were tested for CMV-neutralizing activity using epithelial and fibroblast cells… 
Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization
UCMV virions have a reversible block to epithelial cell entry, suggesting that antibodies may be ineffective in preventing maternal oral CMV acquisition but may limit viral spread in blood or tissues, thereby reducing or preventing fetal infection and disease.
Cytomegalovirus vaccines.
  • M. Mcvoy
  • Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2013
Inclusion of epitopes derived from the pentameric complex may provide enhanced efficacy by inducing potent neutralizing/spread-inhibiting antibodies that target virus replication in a broad spectrum of cell types.
Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures.
A High-Affinity Native Human Antibody Neutralizes Human Cytomegalovirus Infection of Diverse Cell Types
The most potent clone of HCMV-specific immunoglobulin, TRL345, was effective at controlling an ex vivo infection of human placental anchoring villi and is a candidate for clinical evaluation.
Development of a High-Throughput Assay To Measure the Neutralization Capability of Anti-Cytomegalovirus Antibodies
It is demonstrated that a robust high-throughput infection assay can analyze the early steps of the CMV life cycle and quantify the potency of biological reagents to attenuate a virus infection.
Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy
This review summarizes recent findings in the development of HCMV vaccines and key considerations that should be taken into vaccine design based on improved understanding of natural H CMV immunity.
Non-Invasive Detection of Viral Antibodies Using Oral Flocked Swabs
Oral flocked swabs are an easy, self-collection method for measuring viral antibodies and are highly sensitive for CMV, VZV, and EBV IgG, which is potentially useful for surveillance and clinical microbiology.


Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.
Because antibodies against human cytomegalovirus (HCMV) glycoprotein B (gB) neutralize, levels of IgG, secretory IgA (sIgA), and mucosal IgA1 antibodies to HCMV were measured in saliva and nasal washes and correlated with IgG to gB in mucosal samples.
Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
A vaccine that induces immune responses equal to those induced by wild type virus may protect healthy women from acquiring HCMV from their children.
Vaccine prevention of maternal cytomegalovirus infection.
CMV glycoprotein B vaccine has the potential to decrease incident cases of maternal and congenital CMV infection and was more likely to remain uninfected during a 42-month period than the placebo group.
Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.
Conventional determination of the neutralizing activity of human sera in fibroblasts is misleading because antibody response to HCMV pUL131A, pUL130 and pUL128 locus products, which are required for endothelial/epithelial cell infection, provided a potential molecular basis for such a differentialneutralizing activity.
Cytomegalovirus Infections among African-Americans
Sibling-to-sibling transmission was a likely source of CMV infections for the children and the next generation of African-American women may be highly susceptible to a primary CMV infection during pregnancy and may benefit from a CMV vaccine.
Cytomegalovirus Infections
The human consequences of latent infection with CMV are not yet fully appreciated, and future research on this virus with multifaceted potential will need to focus on this issue.
Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.
Information is summarized about the changing epidemiology of CMV and immune responses to infection and immunity, and the current status of several vaccine candidates are reviewed.
Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex
This study describes unusually potent neutralizing antibodies against HCMV that might be used for passive immunotherapy and identifies, through the use of such antibodies, novel antigenic targets in H CMV for the design of immunogens capable of eliciting previously unknown neutralizing antibody responses.
Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children
Testing saliva provides a sensitive and specific alternative to obtaining serum in preschool children and finds an association between cytomegalovirus infection and salivary immunoglobulin G antibodies to CMV glycoprotein B.